PT  - JOURNAL ARTICLE
AU  - Alona Kuzmina
AU  - Yara Khalaila
AU  - Olga Voloshin
AU  - Ayelet Keren-Naus
AU  - Liora Bohehm
AU  - Yael Raviv
AU  - Yonat Shemer-Avni
AU  - Elli Rosenberg
AU  - Ran Taube
TI  - SARS CoV-2 escape variants exhibit differential infectivity and neutralization sensitivity to convalescent or post-vaccination sera
AID  - 10.1101/2021.02.22.21252002
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.22.21252002
4099  - http://medrxiv.org/content/early/2021/02/24/2021.02.22.21252002.short
4100  - http://medrxiv.org/content/early/2021/02/24/2021.02.22.21252002.full
AB  - Towards eradicating COVID19, developing vaccines that induce high levels of neutralizing antibodies is a main goal. As counter measurements, viral escape mutants rapidly emerge and potentially compromise vaccine efficiency. Herein we monitored ability of convalescent or Pfizer-BTN162b2 post-vaccination sera to neutralize wide-type SARS-CoV2 or its UK-B.1.1.7 and SA-B.1.351 variants. Relative to convalescent sera, post-vaccination sera exhibited higher levels of neutralizing antibodies against wild-type or mutated viruses. However, while SARS-CoV2 wild-type and UK-N501Y were similarly neutralized by tested sera, the SA-N501Y/K417N/E484K variant moderately escaped neutralization. Significant contribution to infectivity and sensitivity to neutralization was attributed to each of the variants and their single or combined mutations, highlighting alternative mechanisms by which prevalent variants with either N501Y or E484K/K417N mutations spread. Our study validates the clinical significance of currently administered vaccines, but emphasizes that their efficacy may be compromised by circulated variants, urging the development of new ones with broader neutralization functions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Israeli Mistry of Science and Technology (MOST; grant #3-16897) and the Israel Science Foundation (ISF; Research Grant Application no. 755/17).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in compliance with the ethical principles of the Declaration of Helsinki and was approved by the intuitional ethics committee - Soroka Medical Center - Israel. Helsinki Research Protocol #: 0281-20-SOR (11/6/2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are included within the manuscript